person · Reporting owner

Berk Gregory

Disclosed activity across 2 companies

Tapewire entity: 125332
SEC CIK: 0001306870

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GT Biopharma, Inc.GTBP · Entity 7878	Pres. of R&D, CMO	July 15, 2022	July 20, 2022
Verastem, Inc.VSTM · Entity 5242	Chief Medical Officer	January 09, 2017	January 11, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GT Biopharma, Inc.

Report date July 15, 2022 · Filed July 20, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2032-07-14	Direct	50,000	Reported balance After 2022-07-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-07-15 · Grant · Acquired 50,000 · Balance 50,000

Verastem, Inc.

Report date January 09, 2017 · Filed January 11, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2027-01-09	Direct	150,000	Reported balance After 2017-01-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-01-09 · Grant · Acquired 150,000 · Balance 150,000 F1: 25% of this option will vest on January 9, 2018 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 9, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of this option will vest on January 9, 2018 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 9, 2021.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 15, 2022 Filed Jul 20, 2022 01:44 UTC	GT Biopharma, Inc. GTBP · Entity 7878	GrantOption to purchase Common Stock · Derivative	50,000	$0.00 Strike: $2.48	$0.00	Disclosure SEC source: 0001493152-22-019873 · ownership.xml · derivative · entry 1 Berk Gregory · CIK 0001306870 · Pres. of R&D, CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-14 Read SEC document
February 16, 2021 Filed Feb 14, 2022 22:10 UTC	GT Biopharma, Inc. GTBP · Entity 7878	GrantOption to purchase Common Stock · Derivative	50,000	$0.00 Strike: $6.33	$0.00	Disclosure SEC source: 0001654954-22-001643 · section16.xml · derivative · entry 2 Berk Gregory · CIK 0001306870 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: Represents a grant of options in connection with the reporting person's services as a director. 13rd of the shares underlying the options vest on February 16, 2021, 2022 and 2023. Read SEC document
February 16, 2021 Filed Feb 14, 2022 22:10 UTC	GT Biopharma, Inc. GTBP · Entity 7878	GrantCommon Stock	278,058	$0.00	$0.00	Disclosure SEC source: 0001654954-22-001643 · section16.xml · nonDerivative · entry 1 Berk Gregory · CIK 0001306870 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,058 F1 · shares: Represents a grant of shares of restricted stock ("RSAs") in connection with the reporting person's services as a director. 1/3rd of the RSAs vest on November 11, 2020, 2021 and 2022. The reporting person resigned as a director on April 23, 2021. Read SEC document
January 09, 2017 Filed Jan 11, 2017 17:01 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (Right to Buy) · Derivative	150,000	$0.00 Strike: $1.20	$0.00	Disclosure SEC source: 0001104659-17-001976 · a4.xml · derivative · entry 1 Berk Gregory · CIK 0001306870 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-01-09 F1 · derivative.exercise_date: 25% of this option will vest on January 9, 2018 and 6.25% of this option will vest at the end of each successive three-month period thereafter until January 9, 2021. Read SEC document
October 29, 2016 Filed Nov 1, 2016 20:14 UTC	Verastem, Inc. VSTM · Entity 5242	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001104659-16-153855 · a4.xml · derivative · entry 1 Berk Gregory · CIK 0001306870 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-06-14 F1 · balance_after: On June 14, 2016, the Reporting Person was granted an option to purchase 100,000 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by the end of June, 2017 and the end of June, 2018. 50% of the performance criteria was met on October 29, 2016, resulting in vesting of the option as to 50,000 shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.